PT-141 (Bremelanotide): The Complete Guide

Overview

PT-141, known by its generic name bremelanotide, is a synthetic cyclic heptapeptide that acts on melanocortin receptors in the central nervous system to modulate sexual arousal. It is the first and only FDA-approved treatment that works through central nervous system pathways — rather than vascular mechanisms — to address sexual dysfunction. Marketed under the brand name Vyleesi®, it was approved by the FDA in 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women (FDA Prescribing Information, 2019).

Bremelanotide was developed from Melanotan II, a broader melanocortin receptor agonist originally investigated for skin tanning. During early Melanotan II research, investigators observed unexpected pro-sexual effects in study participants — increased sexual arousal and spontaneous erections in men. This led to the isolation and refinement of PT-141 as a targeted compound for sexual dysfunction, stripped of the tanning-related activity as much as possible (Diamond et al., 2005).

What makes bremelanotide unique among sexual dysfunction treatments is its mechanism. PDE5 inhibitors (sildenafil/Viagra, tadalafil/Cialis) work by enhancing blood flow to the genitals — a peripheral, vascular mechanism. Bremelanotide instead activates melanocortin-4 receptors (MC4R) in the hypothalamus and limbic system, areas of the brain involved in sexual desire and arousal. This central mechanism means it addresses desire and motivation rather than purely mechanical erectile or vascular function (Molinoff et al., 2003).

PT-141 is FDA-approved — a distinction that separates it from the vast majority of peptides used in regenerative and integrative medicine. It has completed Phase 3 clinical trials, undergone full FDA safety and efficacy review, and is available as a commercially manufactured pharmaceutical product. This represents a substantially stronger evidence base than most peptides discussed in this space.

Quick Facts

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

Bremelanotide's mechanism is fundamentally different from all other approved sexual dysfunction treatments. Understanding this distinction is central to understanding what PT-141 does and for whom it may be appropriate.

Melanocortin Receptor System

The melanocortin system is a group of peptide hormones and receptors involved in a wide range of physiological functions including appetite regulation, energy homeostasis, pigmentation, inflammation, and sexual behavior. There are five melanocortin receptor subtypes (MC1R through MC5R), each with different tissue distributions and functions (Molinoff et al., 2003).

Bremelanotide primarily activates two of these receptors:

• MC4R (Melanocortin-4 Receptor): Expressed predominantly in the hypothalamus and other brain regions. MC4R is the primary mediator of bremelanotide's pro-sexual effects. Activation of MC4R in the hypothalamic paraventricular nucleus and medial preoptic area triggers downstream signaling cascades that increase sexual arousal, desire, and motivation. MC4R is also involved in appetite regulation and energy balance — this overlap explains some of bremelanotide's side effects, particularly nausea (Wikberg & Mutulis, 2008).
• MC3R (Melanocortin-3 Receptor): Also expressed in the brain, particularly in the hypothalamus. MC3R contributes to the modulation of sexual behavior and energy homeostasis. Its role in bremelanotide's effects is secondary to MC4R but contributes to the overall response profile (Molinoff et al., 2003).

Central vs. Peripheral Mechanism

The critical distinction between bremelanotide and PDE5 inhibitors:

This central mechanism explains why bremelanotide can address disorders of desire — a psychological and neurological phenomenon — rather than purely mechanical aspects of sexual function. It also explains why it is effective in women, for whom vascular-targeted therapies have generally not been successful for desire disorders (Clayton et al., 2016).

Hypothalamic Pathways

Within the hypothalamus, bremelanotide activates neurons in several key nuclei:

• Medial preoptic area (MPOA): A critical integration center for sexual behavior in both sexes. MC4R activation here increases neuronal firing patterns associated with sexual motivation and copulatory behavior in animal models (Diamond et al., 2005).
• Paraventricular nucleus (PVN): MC4R activation in the PVN triggers downstream release of oxytocin and other neuropeptides involved in sexual arousal and bonding behavior.
• Ventromedial hypothalamus: Involved in female sexual receptivity and lordosis behavior in animal models.

The downstream neurotransmitter effects include modulation of dopamine (associated with desire and reward), oxytocin (associated with arousal and bonding), and potentially norepinephrine pathways — all of which contribute to the subjective experience of sexual desire and arousal (Molinoff et al., 2003).

MC1R and Pigmentation

Bremelanotide retains some affinity for MC1R — the melanocortin receptor primarily responsible for skin pigmentation. MC1R activation stimulates melanocytes to produce melanin, which is why bremelanotide carries a risk of skin hyperpigmentation, particularly with frequent or prolonged use. This is a direct consequence of the peptide's melanocortin receptor activity and is the same mechanism by which its parent compound, Melanotan II, produces skin darkening. The FDA label includes a warning about this risk, particularly for facial and gingival hyperpigmentation that may not fully resolve after discontinuation (FDA Prescribing Information, 2019).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Research

Phase 3: RECONNECT Trials (Pivotal)

The RECONNECT program comprised two randomized, double-blind, placebo-controlled Phase 3 trials that formed the basis for FDA approval. Both studies enrolled premenopausal women diagnosed with HSDD — characterized by persistently low sexual desire causing marked personal distress, not attributable to a medical condition, relationship issues, medication effects, or another psychiatric disorder.

• RECONNECT Study 301: 684 premenopausal women randomized to bremelanotide 1.75 mg SC or placebo, self-administered as needed before anticipated sexual activity. The co-primary endpoints were change from baseline in the Female Sexual Function Index — desire domain (FSFI-D) score and the Female Sexual Distress Scale — Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score (distress related to low sexual desire). At 24 weeks, bremelanotide produced statistically significant improvements in both desire (FSFI-D: +0.5 vs. +0.2, p < 0.001) and reduced distress (FSDS-DAO: −1.0 vs. −0.4, p < 0.001) compared to placebo (Kingsberg et al., 2019).
• RECONNECT Study 302: 630 premenopausal women with HSDD. Results were consistent with Study 301, confirming statistically significant improvements in both sexual desire and reduction in distress associated with low desire. The effect sizes were modest but clinically meaningful in the context of HSDD treatment, where placebo response rates are historically high (Kingsberg et al., 2019).

Key findings from the RECONNECT program:

• Approximately 50% more bremelanotide-treated women achieved a clinically meaningful improvement in desire compared to placebo
• Benefits were observed as early as the first month and were maintained through the 24-week study period
• Nausea was the most common adverse event (~40% vs. ~1% placebo), but was generally mild to moderate and tended to decrease with repeated use
• No significant cardiovascular events occurred, though transient blood pressure increases were observed

Phase 2 Studies in Women

• Dose-finding study: A Phase 2b trial evaluated multiple doses of bremelanotide (0.75 mg, 1.25 mg, 1.75 mg) in premenopausal women with HSDD. The 1.75 mg dose showed the most favorable benefit-risk profile and was selected for Phase 3 development. Higher doses did not provide additional efficacy but increased nausea rates (Clayton et al., 2016).
• Intranasal formulation: Early Phase 2 studies evaluated bremelanotide via intranasal administration. While efficacy signals were observed, the intranasal route was associated with blood pressure increases that led to an FDA clinical hold. Development was subsequently redirected to subcutaneous injection, which produced smaller and more predictable blood pressure changes (Safarinejad, 2008).

Studies in Men

• Erectile dysfunction (Phase 2): A randomized, placebo-controlled Phase 2 study evaluated subcutaneous bremelanotide in men with erectile dysfunction. Bremelanotide produced statistically significant improvements in erectile function compared to placebo, with 60–70% of treated men achieving erections sufficient for intercourse in a clinical monitoring setting. The mechanism appeared distinct from PDE5 inhibitors — bremelanotide induced erections in some men who had not responded to sildenafil (Diamond et al., 2005).
• Combination potential: Preclinical and early clinical data suggest that bremelanotide's central mechanism could complement the peripheral mechanism of PDE5 inhibitors, potentially benefiting men who respond inadequately to PDE5 inhibitors alone. Formal combination studies have not been completed (Molinoff et al., 2003).

Preclinical Mechanism Studies

• MC4R knockout models: Studies in MC4R-deficient mice demonstrated abolition of bremelanotide's pro-sexual effects, confirming MC4R as the primary receptor mediating its sexual function activity (Molinoff et al., 2003).
• Hypothalamic activation: Functional neuroimaging studies in animal models showed that bremelanotide activated hypothalamic regions associated with sexual behavior, including the medial preoptic area and paraventricular nucleus (Diamond et al., 2005).
• Dopamine pathway interaction: Bremelanotide's activation of MC4R leads to downstream dopamine release in mesolimbic pathways — the brain's reward and motivation circuitry — which is thought to contribute to its effects on sexual desire and arousal (Molinoff et al., 2003).

Ongoing and Future Research Directions

• Postmenopausal HSDD: The FDA approval is limited to premenopausal women. Studies evaluating bremelanotide in postmenopausal women are of interest but have not resulted in a label expansion.
• Male sexual dysfunction: Despite promising Phase 2 data, bremelanotide has not been pursued through Phase 3 for male erectile dysfunction, potentially due to the established dominance of PDE5 inhibitors in the market.
• Other melanocortin-mediated conditions: The melanocortin system's involvement in appetite, obesity, and mood suggests potential applications beyond sexual dysfunction, though bremelanotide itself is not being developed for these indications.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Uses

FDA-Approved Indication

Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. HSDD is defined as persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty, and is not better accounted for by another medical condition, substance, medication, or psychiatric disorder. Bremelanotide (Vyleesi®) is FDA-approved for this specific indication based on the RECONNECT Phase 3 trial program (FDA Prescribing Information, 2019).

Off-Label Uses

The following uses are not FDA-approved but are reported in clinical practice. Off-label use of an FDA-approved drug is legal and common in medicine when supported by clinical evidence and prescribed by a licensed provider.

How Bremelanotide Is Accessed

• Vyleesi® (commercial product): Available by prescription as a single-dose autoinjector pen (1.75 mg). Prescribed by OB/GYNs, psychiatrists, sexual medicine specialists, and primary care providers. This is the FDA-approved product manufactured by AMAG Pharmaceuticals / Palatin Technologies.
• Compounding pharmacies: Bremelanotide is also available through compounding pharmacies, which may prepare it in different concentrations or multi-dose vials. Compounded preparations may be used for off-label indications (e.g., male ED) or at provider-specified doses. Compounded products do not carry FDA approval and are prepared under pharmacy compounding regulations.

What Bremelanotide Is NOT Used For

• Skin tanning: Although derived from Melanotan II (a tanning peptide), bremelanotide is not approved or recommended for pigmentation purposes. Its MC1R activity can cause unwanted hyperpigmentation as a side effect.
• Weight loss: While melanocortin receptors are involved in appetite regulation, bremelanotide is not approved or studied for weight management.
• Fertility treatment: Bremelanotide does not enhance fertility and should not be used during pregnancy.
• Performance enhancement: Bremelanotide is not an anabolic or ergogenic agent.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Dosing

FDA-Approved Dosing (Vyleesi®)

Source: FDA Vyleesi® Prescribing Information (2019) · Kingsberg et al., 2019 (Obstetrics & Gynecology) · Clayton et al., 2016 (Journal of Sexual Medicine)

Off-Label Dosing (Compounding)

When prescribed through compounding pharmacies for off-label indications, providers may use different dosing protocols. These are not FDA-approved and are based on clinical experience and Phase 2 data.

Off-label dosing references: Diamond et al., 2005 (Int J Impotence Res) · Clayton et al., 2016 (J Sexual Medicine)

Dosing Limits and Rationale

The frequency limits (1 dose/24 hours, 8 doses/month) are based on the following considerations from clinical trial data:

• Blood pressure effects: Bremelanotide produces transient increases in systolic and diastolic blood pressure (average 2–3 mmHg, peaking ~3–4 hours post-dose). Limiting frequency reduces cumulative cardiovascular exposure (FDA Prescribing Information, 2019).
• Hyperpigmentation risk: MC1R-mediated skin darkening appears to be dose- and frequency-dependent. Limiting monthly doses reduces the risk of focal hyperpigmentation, particularly on the face, gums, and breasts.
• Nausea management: Nausea tends to decrease with repeated use, but excessive dosing frequency may worsen GI tolerability.

Administration Guidance

The Vyleesi® autoinjector is designed for patient self-administration in the abdomen. The autoinjector is a prefilled, single-use device that does not require reconstitution or dose measurement. Proper injection technique should be demonstrated by the prescribing provider or pharmacist before first use.

Storage

• Vyleesi® autoinjector: Store at room temperature (20–25°C / 68–77°F). Do not freeze. Protect from light.
• Compounded bremelanotide (reconstituted): Refrigerate (2–8°C / 36–46°F). Use within the timeframe specified by the compounding pharmacy.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Results: What the Evidence Shows

Clinical Trial Outcomes (Women with HSDD)

Source: Kingsberg et al., 2019 (RECONNECT Phase 3 pooled data)

Timeline of Effects

Results in Men (Phase 2)

Phase 2 data in men with erectile dysfunction showed:

• 60–70% of bremelanotide-treated men achieved erections sufficient for intercourse in a clinical monitoring setting
• Some men who had not responded to PDE5 inhibitors (sildenafil) responded to bremelanotide, suggesting the central mechanism addresses a different component of erectile dysfunction
• Subjective increases in desire and arousal were reported in addition to improved erectile function
• These results have not been confirmed in Phase 3 trials (Diamond et al., 2005)

Factors Affecting Response

• Diagnosis specificity: Bremelanotide was studied in women with HSDD specifically — not general dissatisfaction or relationship-related sexual problems. Appropriate diagnosis improves the likelihood of response.
• Concurrent medications: SSRI use, hormonal contraceptives, and other medications that affect neurotransmitter systems may influence response.
• Nausea management: Nausea is the primary tolerability barrier. Patients who manage through initial nausea (which often diminishes) tend to report better overall outcomes.
• Expectations: Bremelanotide enhances desire — it does not produce artificial arousal independent of context. Realistic expectations improve satisfaction with treatment.

What "Modest Effect Size" Means

The effect sizes in the RECONNECT trials were statistically significant but modest in absolute terms. This is consistent with the broader field of HSDD treatment and reflects several realities:

• Sexual desire is a complex, multifactorial experience influenced by psychological, relational, hormonal, and neurological factors. No single pharmacological intervention is likely to produce dramatic effects in isolation.
• Placebo response rates in sexual dysfunction trials are historically high (20–30%), which narrows the drug-placebo difference.
• The FDA determined that the observed improvements were clinically meaningful despite modest absolute effect sizes, based on the totality of evidence including patient-reported outcomes.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

Side Effects from Clinical Trials

Data from RECONNECT Phase 3 pooled safety analysis. Source: FDA Prescribing Information, 2019

Blood Pressure Effects

Bremelanotide produces transient increases in blood pressure:

• Average increase: 2–3 mmHg systolic, 1–2 mmHg diastolic
• Peak effect: approximately 3–4 hours post-dose
• Returns to baseline within 12 hours
• In the earlier intranasal formulation (higher systemic exposure), larger blood pressure increases were observed, leading to an FDA clinical hold and redirection to subcutaneous dosing

Skin Hyperpigmentation

Bremelanotide's activity at MC1R can cause focal areas of skin darkening, particularly with repeated or prolonged use. Key considerations:

• Reported in approximately 1% of clinical trial participants (likely higher with extended use)
• Most commonly affects the face (perioral, periorbital), gums, and breasts
• Hyperpigmentation may not fully resolve after discontinuation in all cases
• The FDA label specifically warns about this risk and recommends monitoring
• The 8-dose-per-month limit is partly designed to reduce cumulative MC1R activation and pigmentation risk (FDA Prescribing Information, 2019)

Drug Interactions

• Naltrexone: Bremelanotide significantly reduces the systemic exposure of oral naltrexone. Concomitant use is not recommended. A washout period should be observed.
• Antihypertensives: Bremelanotide may cause transient blood pressure increases. Monitor for additive effects or paradoxical responses.
• Drugs slowing GI motility: Bremelanotide may slow gastric emptying. Concomitant use with other drugs that slow GI transit may increase the risk of nausea or delay absorption of oral medications.

Contraindications

• Uncontrolled hypertension — due to transient blood pressure elevation
• Known cardiovascular disease — including recent myocardial infarction, unstable angina, or stroke
• Pregnancy — bremelanotide is classified as Pregnancy Category X (contraindicated in pregnancy)
• Concurrent naltrexone use — significant pharmacokinetic interaction
• Known hypersensitivity to bremelanotide or any component of the formulation

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Regulatory Status

FDA Approval Timeline

What FDA Approval Means

FDA approval of bremelanotide means:

• The drug has undergone rigorous preclinical and clinical evaluation, including Phase 1 (safety/pharmacokinetics), Phase 2 (dose-finding), and Phase 3 (pivotal efficacy) trials
• The FDA reviewed the totality of evidence — efficacy, safety, manufacturing quality, and labeling — and determined that benefits outweigh risks for the approved indication
• The drug is manufactured under current Good Manufacturing Practice (cGMP) standards
• Post-marketing surveillance (Phase 4) is ongoing to monitor for rare or long-term adverse events
• Healthcare providers can prescribe it with confidence that it has met the highest standard of regulatory evaluation

This places bremelanotide in a fundamentally different category from unapproved peptides (e.g., BPC-157, Thymosin Beta-4, GHK-Cu) that have not completed this process.

Compounding Access

In addition to the commercial Vyleesi® product, bremelanotide is available through compounding pharmacies:

• 503A pharmacies: May compound patient-specific bremelanotide preparations with a valid prescription from a licensed provider. This is the pathway for off-label uses (e.g., male ED) and alternative dosing.
• 503B outsourcing facilities: May produce larger batches under more stringent manufacturing requirements.
• Compounded bremelanotide does not carry FDA approval and is not subject to the same manufacturing oversight as the commercial product.

WADA Status

Bremelanotide falls under WADA's prohibited substance framework. Although it is FDA-approved for a therapeutic indication, athletes subject to anti-doping testing should be aware:

• Melanocortin agonists are listed under the prohibited categories
• A Therapeutic Use Exemption (TUE) may be available for athletes with a legitimate HSDD diagnosis, but approval is not guaranteed
• Athletes should consult with their anti-doping authority before use

International Status

Bremelanotide's regulatory status varies by country. It is FDA-approved in the United States. Regulatory submissions and approvals in other major markets (EMA/Europe, MHRA/UK, TGA/Australia) have varied, and availability may differ. Compounding access is generally available in countries that permit pharmacy compounding of approved active pharmaceutical ingredients.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Cost

Typical Pricing

Insurance Coverage

Insurance coverage for Vyleesi® is variable and often limited:

• Commercial insurance: Some plans cover Vyleesi® with prior authorization and documentation of HSDD diagnosis. Coverage varies significantly by plan.
• Prior authorization: Most insurers require documented diagnosis of HSDD, failure of or contraindication to other approaches, and prescriber attestation.
• Copay assistance: The manufacturer offers a savings program that may reduce out-of-pocket costs to as low as $0 for eligible commercially insured patients.
• Compounded bremelanotide: Not covered by insurance, as compounded preparations are not FDA-approved products. All costs are out-of-pocket.
• Off-label use: Insurance coverage for off-label uses (e.g., male ED) is unlikely, even for the commercial product.

Cost Comparison: Bremelanotide vs. Related Treatments

Factors Affecting Cost

• Insurance status: The single largest variable. Patients with commercial insurance and manufacturer copay support may pay near $0; uninsured patients face full retail pricing.
• Frequency of use: The maximum is 8 doses/month. Patients using fewer doses per month will have proportionally lower costs.
• Source: Compounded bremelanotide is substantially less expensive than the commercial product, but does not carry FDA approval and has different quality oversight.
• Provider consultation fees: Initial sexual medicine consultations may add $150–$400 to startup costs.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Questions & Answers

Myth: PT-141 is the same as Melanotan II.

Answer: PT-141 (bremelanotide) was derived from Melanotan II but is a distinct molecule with a different structure, receptor selectivity profile, and clinical application. Melanotan II is a broader melanocortin agonist with significant MC1R activity (skin tanning), appetite suppression effects, and a different safety profile. Melanotan II is not FDA-approved for any indication and is sold only as a research chemical. Bremelanotide was specifically engineered to reduce MC1R activity relative to Melanotan II while preserving MC4R-mediated sexual function effects, though some MC1R activity (and therefore pigmentation risk) remains (Molinoff et al., 2003).

Myth: PT-141 is just Viagra for women.

Answer: Bremelanotide works through an entirely different mechanism than PDE5 inhibitors (Viagra/sildenafil, Cialis/tadalafil). PDE5 inhibitors increase blood flow to genital tissue — a peripheral vascular effect. Bremelanotide activates melanocortin receptors in the brain to enhance sexual desire and arousal — a central nervous system effect. PDE5 inhibitors have consistently failed to improve female sexual desire in clinical trials because desire disorders are not primarily vascular problems. Bremelanotide addresses the neurological component of desire that PDE5 inhibitors do not reach (Clayton et al., 2016).

Myth: PT-141 works instantly like an erection pill.

Answer: Bremelanotide requires approximately 45 minutes to reach onset of action. Its effects are more subtle than PDE5 inhibitors — it increases subjective sexual desire and arousal rather than producing an immediate, obvious physical response. Effects peak within 1–3 hours and may last up to 24 hours. The experience is described in clinical literature as an enhanced receptivity to sexual stimuli and increased desire, not an automatic or involuntary sexual response (FDA Prescribing Information, 2019).

Myth: PT-141 is an unapproved research peptide.

Answer: Bremelanotide is FDA-approved. It completed two Phase 3 clinical trials enrolling over 1,200 patients, underwent full FDA review, and received approval in 2019 as Vyleesi®. It is manufactured under cGMP standards and available by prescription. This places it in a fundamentally different evidence and regulatory category from unapproved peptides. However, when obtained through compounding pharmacies for off-label uses, the compounded preparation does not carry FDA approval — the active ingredient does (Kingsberg et al., 2019).

Myth: PT-141 will make your skin permanently dark.

Answer: Bremelanotide does carry a risk of skin hyperpigmentation due to residual MC1R activity. However, at the FDA-approved dose and frequency limits (1.75 mg, maximum 8 doses/month), the incidence of clinically significant hyperpigmentation in trials was approximately 1%. The risk is dose- and frequency-dependent. Focal hyperpigmentation (face, gums, breasts) is possible and may not fully resolve after discontinuation in all cases. This is distinct from the uniform tanning effect associated with Melanotan II, which has much stronger MC1R activity (FDA Prescribing Information, 2019).

Myth: The nausea means it's dangerous.

Answer: Nausea is the most common side effect of bremelanotide (~40% incidence), but it reflects MC4R activation in brain regions involved in both sexual function and appetite/nausea regulation — not systemic toxicity. Nausea is generally mild to moderate, transient (resolving within hours), and tends to decrease with repeated use. It led to discontinuation in approximately 8% of clinical trial participants. The FDA approved bremelanotide with full knowledge of this side effect, determining that benefits outweighed risks for the indicated population (Kingsberg et al., 2019).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Key Takeaways

Based on the available evidence:

• Bremelanotide (PT-141) is an FDA-approved melanocortin receptor agonist that acts on MC4R and MC3R in the brain to enhance sexual desire and arousal. It is the first centrally-acting treatment approved for sexual dysfunction.
• The evidence base is strong. Two Phase 3 randomized, double-blind, placebo-controlled trials (RECONNECT) in over 1,200 premenopausal women demonstrated statistically significant improvements in sexual desire and reduction in associated distress. This is a substantially higher evidence standard than most peptides in clinical use.
• It is FDA-approved as Vyleesi® for HSDD in premenopausal women. The approved dose is 1.75 mg subcutaneously, as needed, with a maximum of 1 dose per 24 hours and 8 doses per month.
• It works differently from PDE5 inhibitors. Bremelanotide addresses sexual desire through central nervous system pathways, while Viagra/Cialis address erectile function through peripheral vascular mechanisms. This makes bremelanotide effective for desire disorders where vascular treatments have not been successful.
• Phase 2 data in men is promising but has not been confirmed in Phase 3 trials. Off-label use in men for ED and low libido is reported in clinical practice.
• Nausea is the primary tolerability challenge (~40% incidence), but it is generally mild and diminishes with repeated use. Transient blood pressure elevation and skin hyperpigmentation risk are additional considerations.
• Cost ranges from $200–$900/month depending on the source (commercial vs. compounding) and insurance coverage. Manufacturer savings programs may significantly reduce out-of-pocket costs.

Who Might Consider Bremelanotide

Based on the approved indication and available evidence, bremelanotide may be appropriate for individuals who:

• Are premenopausal women diagnosed with HSDD (FDA-approved indication)
• Have experienced persistently low sexual desire causing personal distress, not attributable to relationship problems, medications, or other medical conditions
• Have not responded adequately to non-pharmacological approaches (counseling, relationship therapy)
• Are men with erectile dysfunction or low libido who have not responded to PDE5 inhibitors (off-label, based on Phase 2 data)
• Do not have uncontrolled hypertension or significant cardiovascular disease

Questions to Ask a Provider

• Do I meet the diagnostic criteria for HSDD, and is bremelanotide appropriate for my situation?
• Should I try non-pharmacological approaches first or alongside bremelanotide?
• Is the commercial product (Vyleesi®) or a compounded preparation more appropriate for me?
• What is my insurance coverage, and am I eligible for manufacturer savings programs?
• How should I manage nausea if it occurs?
• Should my blood pressure be monitored during treatment?
• What changes in desire or function should I expect, and on what timeline?
• Are there interactions with my current medications?

Sources & Further Reading

FDA Regulatory Documents

• FDA Vyleesi® (bremelanotide) Full Prescribing Information (2019) — NDA 210557
• FDA Drugs@FDA: Vyleesi Approval History — NDA 210557

Phase 3 Clinical Trials (RECONNECT)

• Kingsberg SA, et al. (2019) — "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials" — Obstetrics & Gynecology

Phase 2 Clinical Studies

• Clayton AH, et al. (2016) — "Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial" — Journal of Sexual Medicine
• Diamond LE, et al. (2005) — "An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141)" — International Journal of Impotence Research
• Safarinejad MR (2008) — "Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder" — Journal of Sexual Medicine

Mechanism of Action

• Molinoff PB, et al. (2003) — "PT-141: A melanocortin agonist for the treatment of sexual dysfunction" — Annals of the New York Academy of Sciences
• Wikberg JES & Mutulis F (2008) — "Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction" — Nature Reviews Drug Discovery

Anti-Doping

• WADA: Prohibited List (current year)

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.